- 2020February 04
Great news! An innovative antibody drug from Gmax approved for conducting clinical trials in the US
On the occasion of the start of the year, a piece of news was sent back from the other side of the ocean that an original monoclonal antibody drug named GMA301 from Gmax has been approved by the US FDA for conducting clinical trials in the US.
- 2020January 21
Big news! The first antibody drug for Pulmonary Arterial Hypertension has been approved for clinical trials in China
GMA301 is the first antibody drug targeting to endothelin receptor A for the treatment of pulmonary arterial hypertension, and is developed by GMAX on its independently constructed g-protein-coupled receptor (GPCR) antibody technology platform.
- 2019June 14
Strong Team - Four Senior Experts Join Gmax Biopharm
They will provide Gmax with scientific and strategic advisory on R&D, global multi-center clinical trials, international business development and IPO, etc.
- 2018December18
GMAX initiates the multi-region, multi-center clinical trial of Getagozumab in PAH patients
GMAX initiated the multi-region, multi-center clinical trial of Getagozumab in pulmonary arterial hypertension (PAH) patients.
- 2018December10
Gmax long-acting GLP-1R agonist has been approved by the China Human Genetic Resources Management to start clinical trials
GMA102 has been approved for the IND in August 2018, in China. GMAX has initiated a multi-center, randomized, double-blinded, placebo controlled clinical trial in China.